Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis

X
Trial Profile

A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ofatumumab (Primary) ; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ASCLEPIOS II
  • Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
  • Most Recent Events

    • 18 Apr 2024 Results of subgroup analysis from the phase 3 ASCLEPIOS I/II trials assessing prognostic value of Serum Neurofilament Light Chain for future disease activity according to BMI and age in Patients With Relapsing Multiple Sclerosis presented at the 76th Annual Meeting of the American Academy of Neurology 2024
    • 18 Apr 2024 Results from Phase 3 ASCLEPIOS I/II and ALITHIOS assessing longer-term (Up to 6 Years) Efficacy of Ofatumumab presented at the 76th Annual Meeting of the American Academy of Neurology 2024
    • 02 Mar 2024 Results of subgroup analysis from the phase 3 ASCLEPIOS I/II trials assessing prognostic value of Serum Neurofilament Light Chain for future disease activity according to BMI and age in Patients With Relapsing Multiple Sclerosis presented at the Americas Committee for Treatment.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top